Login to Your Account



Scenesse Misses EPP Phase III Endpoint, but Still on Track

By Cormac Sheridan
Staff Writer

Wednesday, November 13, 2013
Scenesse (afamelanotide), which Clinuvel Pharmaceuticals Ltd. is developing for the rare light intolerance disorder erythropoietic protoporphyria (EPP), failed to hit the endpoint of a U.S. Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription